Lead Product(s) : Astressin B
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Neurocrine Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration will utilize Sentia’s proprietary peptide-based platform and Neurocrine’s drug development expertise in CRF biology to develop and commercialize medicines with the potential to treat a variety of hypothalamic-pituitary-adrenal (HPA)...
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Undisclosed
April 27, 2021
Lead Product(s) : Astressin B
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Neurocrine Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?